Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 12, 2026The Journal of Experimental Medicine

Leveraging cDC1 biology and function for enhanced immunotherapy

View Full Paper
Ask AI
Bookmark
Share

Authors

RWRoss W. WardTisch HospitalUKUddipan KarIcahn School of Medicine at Mount SinaiSBSreekumar BalanMount Sinai Hospital

Discussion

Loading...

Member takes

Implication

Randomized trial explores cDC1 biology to improve immunotherapy efficacy, suggesting new treatment strategies.

Key Points

  • This research aims to understand how conventional type 1 dendritic cells (cDC1s) can be enhanced for better cancer immunotherapy outcomes.
  • Discussion of mechanisms enabling cDC1-mediated immunity and those that suppress it.
  • Evaluation of strategies to augment cDC1 numbers and reprogram their function.
  • Assessment of prognostic value of cDC1-related signatures.
  • Improved patient outcomes are associated with functional cDC1 populations.
  • Emerging strategies show potential to enhance cDC1 interactions with CD8+ and CD4+ T cells.
  • Identification of key signaling axes in the tumor microenvironment affecting cDC1 activity.

Cite This Study

Ward et al. (2026) studied this question.

synapsesocial.com/papers/6a2ba29a8101cf8926f01840https://doi.org/10.1084/jem.20241199
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Identity, Functions, and the Spatiotemporal Maturation of Type 1 Conventional Dendritic Cells2025 · 5 citations
  2. 2Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer2024 · 16 citations
  3. 3Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy2024 · 25 citations
  4. 4Depletion of Conventional Type-1 Dendritic Cells in Established Tumors Suppresses Immunotherapy Efficacy2022 · 37 citations
  5. 5BDCA1+ cDC2s, BDCA2+ pDCs and BDCA3+ cDC1s reveal distinct pathophysiologic features and impact on clinical outcomes in melanoma patients2020 · 28 citations